Q-omics provides the consensus-scored C18orf25 profile across patient tissues and cancer cell-line models. C18orf25 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, C18orf25 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, C18orf25 RNA expression shows 21,011 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where C18orf25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C18orf25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C18orf25 survival associations across molecular data types. C18orf25 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C18orf25 RNA expression–survival associations across cancer types. High C18orf25 expression shows unfavorable associations in ACC, LIHC, LGG, MESO and SCLC, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for C18orf25 RNA expression.
This table summarizes C18orf25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C18orf25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C18orf25 shows lower tumor expression in THCA and COAD and higher tumor expression in LIHC, CHOL, LUSC and BRCA. The LIHC box plot shows higher C18orf25 RNA expression in tumor versus normal tissue (log2 FC = +0.586, t-test p < 0.001).
This table shows molecular features associated with C18orf25 in patient tissues and cancer cell lines. In patient samples, C18orf25 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C18orf25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
